Literature DB >> 8398697

Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.

N E Heldin1, K Usuki, J Bergh, B Westermark, C H Heldin.   

Abstract

In the present investigation we have studied the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in ten different human lung carcinoma cell lines, four small cell carcinomas and six non-small cell carcinomas. None of the small-cell lung carcinoma cell lines demonstrated expression of PD-ECGF/TP mRNA. However, four of six of the non-small cell carcinoma cell lines expressed the 1.8 kb PD-ECGF/TP transcript. The cell lines derived from the single squamous cell carcinoma and the two adenocarcinomas expressed the PD-ECGF/TP mRNA, and were found to have the corresponding protein both in cell lysates and conditioned media as determined both by immunoblotting and measurement of thymidine phosphorylase activity. Only one of three studied large cell carcinoma cell lines expressed low levels of PD-ECGF/TP mRNA, but the corresponding PD-ECGF/TP protein was not demonstrated by immunoblotting.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398697      PMCID: PMC1968610          DOI: 10.1038/bjc.1993.414

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor.

Authors:  F Ishikawa; K Miyazono; U Hellman; H Drexler; C Wernstedt; K Hagiwara; K Usuki; F Takaku; W Risau; C H Heldin
Journal:  Nature       Date:  1989-04-13       Impact factor: 49.962

2.  Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines.

Authors:  G Bepler; G Jaques; K Neumann; G Aumüller; C Gropp; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

Authors:  A F Gazdar; D N Carney; M M Nau; J D Minna
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

4.  The expression of the platelet-derived and transforming growth factor genes in human nonsmall lung cancer cell lines is related to tumor stroma formation in nude mice tumors.

Authors:  J Bergh
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

5.  High-yield purification of platelet-derived endothelial cell growth factor: structural characterization and establishment of a specific antiserum.

Authors:  K Miyazono; C H Heldin
Journal:  Biochemistry       Date:  1989-02-21       Impact factor: 3.162

6.  Purification and properties of an endothelial cell growth factor from human platelets.

Authors:  K Miyazono; T Okabe; A Urabe; F Takaku; C H Heldin
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

7.  Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines.

Authors:  G Söderdahl; C Betsholtz; A Johansson; K Nilsson; J Bergh
Journal:  Int J Cancer       Date:  1988-04-15       Impact factor: 7.396

8.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.

Authors:  F Cuttitta; D N Carney; J Mulshine; T W Moody; J Fedorko; A Fischler; J D Minna
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

9.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06

10.  Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma).

Authors:  H Baillie-Johnson; P R Twentyman; N E Fox; G A Walls; P Workman; J V Watson; N Johnson; J G Reeve; N M Bleehen
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

View more
  7 in total

1.  Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA.

Authors:  Y Kato; S Matsukawa; R Muraoka; N Tanigawa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 2.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.

Authors:  N S Brown; R Bicknell
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

3.  Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.

Authors:  M I Koukourakis; A Giatromanolaki; K J O'Byrne; M Comley; R M Whitehouse; D C Talbot; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.

Authors:  L Griffiths; I J Stratford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Yuka Asano; Shinichiro Kashiwagi; Naoyoshi Onoda; Satoru Noda; Hidemi Kawajiri; Tsutomu Takashima; Masahiko Ohsawa; Seiichi Kitagawa; Kosei Hirakawa
Journal:  PLoS One       Date:  2016-07-29       Impact factor: 3.240

6.  Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor / thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470.

Authors:  J Mori; M Haisa; Y Naomoto; M Takaoka; M Kimura; T Yamatsuji; K Notohara; N Tanaka
Journal:  Jpn J Cancer Res       Date:  2000-06

7.  The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium.

Authors:  S B Fox; M Westwood; A Moghaddam; M Comley; H Turley; R M Whitehouse; R Bicknell; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.